title: [Clinico-pathological study and appraisal of treatment for endometrial cancer at the Ehime University Hospital].
abstract: Clinical and pathological studies were performed on 51 cases with endometrial cancer. The results are as follows: The average age was 58.9 years and the range 41 to 80 years. Forty-one (80.4%) patients were postmenopausal and the average menopausal age was 49.1 years. All cases were symptomatic and in 35 (76.5%) cases the postmenopausal bleeding was noted as a chief complaint. The chief complications were obesity (37.5%), hypertension (25.0%), infertility (13.7%) and diabetes mellitus (9.4%). Of 51 cases, 36(70.6%) were in Stage I, 7(13.7%) in Stage II, 6(11.8%) in Stage III and 2(3.9%) in Stage IV. When the depth of the invasion was classified into 3 grades, less than 1/3 of the muscular layer, between 1/3 and 2/3, and over 2/3 in 48 cases examined, they were observed in 20(41.7%), 10(20.8%) and 18 cases (37.5%) respectively. There were 6 cases (15%) with lymph node involvement in 40 cases examined. Those in which the depth of invasion was over 2/3, had a significantly higher incidence of lymph node involvement. The five year cumulative survival rate was 66.7%(14/21) for all cases. The clinical stage and age of the patients had a significant correlation with the prognosis of endometrial cancer, but the histological grades, the depth of invasion, and lymph node involvement did not demonstrate the a significant correlation in prognosis in this study. The five year survival rate for the group treated by modified pan-hysterectomy with pelvic lymphadenectomy was 92.3% which was significantly higher than the 25% of the group treated by simple hysterectomy or than the 0% of non-surgical group.(ABSTRACT TRUNCATED AT 250 WORDS)
mesh_terms: D000230:Adenocarcinoma / Q000628:therapy; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002294:Carcinoma, Squamous Cell / Q000628:therapy; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D014594:Uterine Neoplasms / Q000401:mortality / Q000628:therapy*